{"database":"bioimages","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Kasper Fugger"],"journal":["The Journal of Cell Biology"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-JCBD-200812138"],"attach_to":["JCB"],"legend":["U2OS/GFP-hFbh1 WT cells were left untreated for 24 h, and subjected to IR for 1 h. The cells were then pre-extracted to remove soluble proteins, fixed and co-immunostained with RPA and Rad51 antibodies.","U2OS/NLS-GFP-hFbh1 WT cell line was induced with DOX in the presence of BrdU for 24 h. Cells were treated with HU for 1 h, pre-extracted, fixed and co-immunostained with RPA (red) and Rad51 (blue).","EMSA with hFbh1, using 32P-labelled ssDNA or dsDNA probes, which were incubated with increasing amounts (200-1000 nM) of GST-hFbh1 and subjected to native gel electrophoresis. The resulting GST-hFbh1/probe complex is seen as a slower migrating band.","U2OS/GFP-hFbh1 WT cells were induced with DOX for 24 h, and subjected to HU for 2 h. The cells were then pre-extracted to remove soluble proteins, fixed and co-immunostained with RPA and Rad51 antibodies.","U2OS cells expressing GFP-hFbh1 were transfected with indicated siRNAs for 24 h. One day later, cells were induced with DOX for an additional 24 h, and subsequently exposed to HU for 1 h.","U2OS/NLS-GFP-hFbh1 *HL cell line was induced with DOX in the presence of BrdU for 24 h. Cells were treated with HU for 1 h, fixed and co-immunostained with BrdU (red) and Cyclin A (blue).","IR-treated U2OS cells expressing GFP-hFbh1. One hour after treatment, cells were fixed and co-immunostained with antibodies to RPA (red) and γ-H2AX (violet).","U2OS cells expressing GFP-hFbh1 were labelled with BrdU for 24 h, and subsequently treated with HU for 1h. Cells were fixed and stained for BrdU (red).","Mock treated U2OS cells expressing GFP-hFbh1. One hour after treatment, cells were fixed and co-immunostained with antibodies to RPA (red) and γ-H2AX (violet).","U2OS/NLS-GFP-hFbh1 WT cell line was uninduced in the presence of BrdU for 24 h. Cells were treated with HU for 1 h, pre-extracted, fixed and co-immunostained with RPA (red) and Rad51 (blue).","U2OS cells expressing GFP-hFbh1 were treated with HU, and collected at the indicated time points. Cells were fixed and co-immunostained for RPA (red).","U2OS cells expressing GFP-hFbh1 were transfected with indicated siRNAs for 24 h. One day later, cells were induced with DOX for an additional 24 h, and subsequently exposed to IR and collected after 1 h.","U2OS/NLS-GFP-hFbh1 WT cell line was induced with DOX in the presence of BrdU for 24 h. Cells were treated with HU for 1 h, fixed and co-immunostained with BrdU (red) and Cyclin A (blue).","HU-treated U2OS cells expressing GFP-hFbh1. One hour after treatment, cells were fixed and co-immunostained with antibodies to RPA (red) and γ-H2AX (violet).","U2OS/GFP-hFbh1 WT cells were induced with DOX for 24 h, and subjected to IR for 1 h. The cells were then pre-extracted to remove soluble proteins, fixed and co-immunostained with RPA and Rad51 antibodies.","IR-treated U2OS cells expressing GFP-hFbh1. One hour after treatment, cells were labelled with BrdU for 30 minutes, fixed and co-immunostained with antibodies to BrdU (red) and Cyclin A (blue).","U2OS/GFP-hFbh1 cells were induced with DOX for 24 h, and irradiated with UV-C (100 J/m2) through a polycarbonate filter with 5 μm pores. Thirty min later, cells were fixed and immunostained with Cyclin A antibody.","U2OS/GFP-hFbh1 WT cells were left untreated for 24 h, and subjected to HU for 2 h. The cells were then pre-extracted to remove soluble proteins, fixed and co-immunostained with RPA and Rad51 antibodies.","U2OS/sh-hFbh1 cells were induced with Dox for 48 h, and incubated in the presence of BrdU for an additional 24 h. Cells were then treated with HU for 2 h, and processed for native fixation and immunostaining with BrdU antibody and DAPI.","U2OS/sh-hFbh1 cells were left untreated for 48 h, and incubated in the presence of BrdU for an additional 24 h. Cells were then treated with HU for 2 h, and processed for native fixation and immunostaining with BrdU antibody and DAPI.","U2OS/NLS-GFP-hFbh1 WT cell line was uninduced in the presence of BrdU for 24 h. Cells were treated with HU for 1 h, fixed and co-immunostained with BrdU (red) and Cyclin A (blue).","IR-treated U2OS cells expressing GFP-hFbh1. One hour after treatment, cells were fixed and co-immunostained with antibodies to RPA (red) and Cyclin A (magenta).","BJ cells were transfected with control or hFbh1 siRNAs for 48 h and subjected to sister chromatid exchange (SCE) analysis. Image shows a representative metaphase chromosome spread from hFbh1-depleted cells.","U2OS/NLS-GFP-hFbh1 *HL cell line was induced with DOX in the presence of BrdU for 24 h. Cells were treated with HU for 1 h, pre-extracted, fixed and co-immunostained with RPA (red) and Rad51 (blue).","U2OS cells expressing GFP-hFbh1 were transfected with indicated siRNAs for 24 h. One day later, cells were induced with DOX for an additional 24 h, and subsequently exposed to IR for 1 h.","Micro-irradiated U2OS cells expressing GFP-hFbh1. One hour after treatment, cells were fixed and co-immunostained with antibodies to RPA (red) and γ-H2AX (violet).","U2OS/NLS-GFP-hFbh1 *FB cell line was induced with DOX in the presence of BrdU for 24 h. Cells were treated with HU for 1 h, fixed and co-immunostained with BrdU (red) and Cyclin A (blue)."],"repository":["bioimages"],"figure_sub":["Image 782 (Figure 4 - B)","Image 763 (Figure 1 - C)","Image 755 (Figure 1 - A)","Image 3797 (Figure 4 - D)","Image 769 (Figure 2 - A)","Image 3793 (Figure 3 - A)","Image 759 (Figure 1 - C)","Image 778 (Figure 4 - B)","Image 771 (Figure 2 - B)","Image 761 (Figure 1 - C)","Image 3791 (Figure 2 - D)","Figure 1 - A","Image 760 (Figure 1 - C)","Image 753 (Figure 1 - A)","Figure 1 - C","Figure 1 - B","Image 3800 (Figure 2 - A)","Figure 2 - C","Figure 2 - D","Figure 2 - A","Figure 2 - B","Image 779 (Figure 4 - B)","Image 757 (Figure 1 - B)","Image 3788 (Figure 2 - A)","Image 765 (Figure 2 - A)","Image 764 (Figure 1 - C)","Figure 3 - A","Image 3794 (Figure 3 - A)","Figure 4 - B","Image 762 (Figure 1 - C)","Image 781 (Figure 4 - B)","Image 768 (Figure 2 - A)","Image 777 (Figure 4 - B)","Image 3798 (Figure 4 - D)","Image 754 (Figure 1 - A)","Figure 4 - D","Image 767 (Figure 2 - A)","Figure 5 - A","Image 770 (Figure 2 - A)","Image 776 (Figure 4 - B)","Image 784 (Figure 5 - A)","Image 3795 (Figure 3 - A)","Image 775 (Figure 4 - B)","Figure 5","Image 756 (Figure 1 - A)","Figure 4","Image 766 (Figure 2 - A)","Image 774 (Figure 2 - C)","Image 758 (Figure 1 - B)","Image 3796 (Figure 3 - A)","Image 780 (Figure 4 - B)","Figure 1","Figure 3","Figure 2"],"pubmed_authors":["Jannie Rendtlew Danielsen","Jiri Bartek","Niels Mailand","Jacob Falck","Jiri Lukas","Kasper Fugger","Christoffel Dinant","Martin Mistrik"],"additional_accession":[]},"is_claimable":false,"name":"Human Fbh1 helicase contributes to genome maintenance via pro- and anti-recombinase activities","description":null,"dates":{"release":"2009-09-07T11:17:21Z","modification":"2018-11-29T11:17:21Z","creation":"2018-11-29T11:17:21Z"},"accession":"S-JCBD-200812138","cross_references":{"doi":["10.1083/jcb.200812138"]}}